Probiotics for NAFLD

Compounds that bind to the farnesoid X receptor (FXR) as agonists or modulators for treating diseases like cholestatic conditions, liver fibrosis, obesity, diabetes, metabolic disorders, inflammatory bowel disease, lipid disorders, stroke, thrombosis, infections, cancer, and liver steatosis. The compounds have structures with specific substituents on the aromatic ring and side chain. They can be used to develop drugs for treating these conditions by activating FXR signaling.

Source

A treatment for fatty liver disease and fibrotic liver disease, including alcoholic liver disease and non-alcoholic fatty liver disease, comprising a combination of fermented cereal composition and probiotic microorganisms, preferably anti-inflammatory Lactobacillus plantarum strains 299 and 299v. The treatment involves daily administration of a ready-to-use fermented cereal composition, which can be formulated with or without postbiotics such as short-chain fatty acids, to prevent disease progression, initiate regression, or postpone progression of liver disease.

Source

A compound, HK4, is disclosed for the treatment and prevention of non-alcoholic fatty liver disease (NAFLD) and related conditions. HK4 prevents palmitate-induced apoptosis in hepatocytes and potentiates GABA effects, reducing inflammation and cell death associated with NAFLD progression. The compound is administered in a therapeutically effective amount to alleviate NAFLD symptoms and prevent disease progression.

Source

A method for treating or preventing non-alcoholic steatohepatitis (NASH) using a thyroid hormone receptor-β (THR-β) agonist, such as resmetirom, which reduces liver inflammation and fibrosis. The method involves administering the THR-β agonist to a subject with NASH, either as a standalone treatment or in combination with other therapies, to achieve a significant reduction in liver enzymes and fibrosis markers.

Source

A novel probiotic drug for preventing and treating metabolic diseases, comprising Nosocomiicoccus massiliensis, a Gram-positive bacterium isolated from hospital environments. The probiotic activates GPR120, MC4R, and APJ receptors, targets for obesity and diabetes treatment, and reduces body weight, blood sugar, and lipid metabolism indicators in obese mice.

Source

Combination therapy for treating metabolic diseases, comprising a PPAR full agonist and a THR-β agonist, which synergistically regulates lipid metabolism, insulin sensitivity, and liver function to improve conditions such as obesity, diabetes, hyperlipidemia, NASH, and chronic kidney disease.

Source

Pharmaceutical composition for preventing or treating alcoholic and non-alcoholic fatty liver disease, comprising ATPase inhibitory factor 1 (IF1) as an active ingredient. IF1, a human-derived protein, protects hepatocytes from alcohol toxicity, prevents lipid accumulation, suppresses liver fibrosis and inflammation, and modulates gut microbiota.

Source

Compositions and methods for inhibiting cell death-inducing DFFA-like effector B (CIDEB) gene expression, particularly for treating liver diseases such as nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The compositions comprise double-stranded RNA (dsRNA) agents that specifically target CIDEB mRNA, and the methods involve administering these agents to inhibit CIDEB expression and treat associated diseases.

Source

A method of treating liver diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) by administering a double-stranded short interfering nucleic acid (siNA) molecule that targets the HSD17B13 gene. The siNA molecule comprises a sense strand and an antisense strand, each with a nucleotide sequence that is at least 60% identical to a corresponding sequence in the HSD17B13 gene. Administration of the siNA molecule reduces HSD17B13 expression in hepatocytes, thereby treating liver diseases.

Source

Engineering bacteria for preventing and treating non-alcoholic steatohepatitis (NASH) through genetic modification to produce polyphenolic compounds with therapeutic activity. The engineered bacteria, such as E. coli Nissle 1917, are designed to synthesize compounds like p-coumaric acid that have anti-inflammatory, fat-reducing, and insulin-resistance-improving effects. The bacteria are engineered to convert glucose into tyrosine and then into p-coumaric acid through heterologous expression of tyrosine aminotransferase. The engineered bacteria can be administered orally to treat NASH and maintain a sustained release of the therapeutic compound.

Source

siRNA for inhibiting CIDEB gene expression, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are complementary, and the sequence thereof is selected from any group of duplexes shown in Table 1 or at least 15 consecutive nucleotide sequences that differ from the duplexes by no more than 3 nucleotides. The siRNA is used to treat diseases associated with CIDEB expression, including hepatitis, liver fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), cirrhosis, alcoholic steatohepatitis (ASH), alcoholic fatty liver disease (ALD), HCV-related cirrhosis, drug-induced liver damage and hepatocellular necrosis.

Source

Peptides derived from the SOCS1 protein inhibit the JAK/STAT signaling pathway to prevent and treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The peptides, which are cell-permeable and can be administered orally, reduce liver inflammation, fibrosis, and metabolic dysfunction in animal models of NAFLD. They specifically target the JAK/STAT pathway, which is dysregulated in NAFLD, and have been shown to prevent the progression of NAFLD to NASH and cirrhosis.

Source

A pyridazinone compound with thyroid hormone receptor beta (TRβ) agonist activity for treating metabolic disorders such as non-alcoholic steatohepatitis (NASH), obesity, atherosclerosis, and hyperlipidemia. The compound selectively activates TRβ receptors without the cardiac stimulation and bone resorption side effects associated with thyroid hormone replacement therapy. It has a novel chemical structure that combines a pyridazinone core with a specific aniline and triazine moiety, providing improved selectivity and pharmacokinetic properties compared to existing TRβ agonists.

Source

Methods for treating metabolic diseases and disorders using thyroid hormone receptor agonists that selectively activate thyroid hormone receptor beta (THRβ) without suppressing the thyroid hormone axis. The compounds, which include novel chemical entities, are designed to modulate lipid metabolism, reduce liver fat content, and prevent or treat nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) without affecting thyroid function or circulating thyroid hormone levels.

Source

A synbiotic composition for treating non-alcoholic fatty liver disease (NAFLD) comprising a prebiotic phytonutrient fibre material prepared from sugarcane and at least one probiotic bacterial strain. The prebiotic fibre material is derived from virgin sugarcane with the sugar removed, and the probiotic strain is selected for its ability to survive gastric transit and generate beneficial fermentation products. The synbiotic composition is administered in a food product or therapeutic formulation to modulate gut microbiota and reduce inflammation associated with NAFLD.

Source

Microorganism that can be used in the preparation of health foods or drugs for the prevention and treatment of non-alcoholic fatty liver disease. The microorganism includes Akermansia muciniphila, a probiotic combination product, and pharmaceutical excipients.

Source

Methods of treating and preventing liver diseases, including non-alcoholic steatohepatitis (NASH) and liver fibrosis, by administering a combination of an acetyl-CoA carboxylase (ACC) inhibitor and a farnesoid X receptor (FXR) agonist. The combination reduces liver damage, fibrosis, and inflammation, and can be used to treat various liver diseases, including NASH, liver fibrosis, and primary sclerosing cholangitis (PSC).

Source

Polymorphs of the SSAO inhibitor Compound I, including Form II, which exhibits improved stability and crystallinity compared to the known Form I. The polymorphs are prepared through controlled crystallization methods, such as evaporation of a solvent mixture or addition of an anti-solvent, and are useful in the treatment of liver disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Source

Treatment of non-alcoholic fatty liver disease (NAFLD) by administering a compound that reduces expression of HSD17B13, a protein involved in lipid metabolism, through RNA interference. The compound is a double-stranded oligonucleotide linked to a ligand, administered at a dose of 25-200 mg, and repeated every 4-12 weeks. The treatment reduces HSD17B13 mRNA and protein levels by at least 50% and 30%, respectively, as measured by qRT-PCR and Western Blot.

Source

A composition for treating inflammatory diseases comprising live Adlercreutzia bacteria, particularly Adlercreutzia equolifaciens, and/or culture extracts thereof. The composition is used to prevent or treat inflammatory diseases such as non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel diseases (IBD) by modulating the gut microbiota and reducing inflammation.

Source